VanEck Associates’s Repligen RGEN Stock Holding History
Bought
Maintained
Sold
Other funds holding RGEN
UCFA
MC
WA
VanEck Associates's RGEN Position: Q2 2026 in Review
VanEck Associates increased its Repligen (RGEN) stake by 174% in Q2 2026, buying an estimated $1.39M and bringing the position to 17,887 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1003.
VanEck Associates first reported a position in RGEN in Q1 2021 and has held it in 22 quarters since. The position peaked at $11M in Q4 2022. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.
- VanEck Associates held 17,887 shares of Repligen worth $2.44M as of Q2 2026.
- VanEck Associates bought 11,354 Repligen shares in Q2 2026, an estimated $1.39M.
- Repligen made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #1003 holding.
- VanEck Associates first reported a position in Repligen in Q1 2021 and has held it in 22 quarters since.
- VanEck Associates's Repligen position peaked at $11M in Q4 2022.
- 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.